Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to provide the following update on its business activities for the three months to 31 December 2025 and subsequent to the period end.
Appointment of new CEO and Managing Director, Mr David Morris
Appointment of Non-Executive Director, Ms Vicki Robinson
Commenced a strategic and operational review
Received $2.2 million in R&D tax incentive
Cash outflow from operations was $182,000 for the quarter ended 31 December 2025; this includes receipt of $2,687,000 from R&D tax incentive and government grants
Received $692,288 from the exercise of 1,384,576 options as at 29 January 2026.
Cash position of $7.7 million as at 31 December 2025
View here: Article
For further information please contact:
David Morris
CEO and Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
Dirk van Dissel
Investor Relations and Corporate Advisory Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au